Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Buffalo, NY
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
New Hyde Park, NY
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
New York, NY
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Valhalla, NY
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Valhalla, NY
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Charlotte, NC
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Akron, OH
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Cleveland, OH
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Cleveland, OH
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Columbus, OH
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Portland, OR
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Portland, OR
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Dallas, TX
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Houston, TX
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Houston, TX
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
San Antonio, TX
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Charlottesville, VA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Norfolk, VA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Richmond, VA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Seattle, WA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Washington,
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
mi
from
Edegem,
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
mi
from
Edegem,
Click here to add this to my saved trials
Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant
A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Acute Humoral Rejection (AHR) in Positive Crossmatch Deceased Donor Kidney Transplantation
Status: Enrolling
Updated:  1/8/2018
The Mayo Clinic
mi
from
Rochester, MN
Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant
A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Acute Humoral Rejection (AHR) in Positive Crossmatch Deceased Donor Kidney Transplantation
Status: Enrolling
Updated: 1/8/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
The Everolimus-Transplant Exit Strategy Trial (E-TEST)
Zortress (Everolimus) to Prevent Alloantibody Formation in Patients With Late Stage Renal Allograft Failure: The Everolimus-Transplant Exit Strategy Trial (E-TEST)
Status: Enrolling
Updated:  1/9/2018
Emory University
mi
from
Atlanta, GA
The Everolimus-Transplant Exit Strategy Trial (E-TEST)
Zortress (Everolimus) to Prevent Alloantibody Formation in Patients With Late Stage Renal Allograft Failure: The Everolimus-Transplant Exit Strategy Trial (E-TEST)
Status: Enrolling
Updated: 1/9/2018
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study to Evaluate Daptomycin Given During Dialysis and After Dialysis
A Prospective, Randomized, Crossover-design Study to Evaluate the Pharmacokinetics and Safety of Daptomycin Administered at 9 mg/kg During and 6 mg/kg After Hemodialysis
Status: Enrolling
Updated:  1/10/2018
West Coast Clinical Trials, LLC
mi
from
Cypress, CA
Study to Evaluate Daptomycin Given During Dialysis and After Dialysis
A Prospective, Randomized, Crossover-design Study to Evaluate the Pharmacokinetics and Safety of Daptomycin Administered at 9 mg/kg During and 6 mg/kg After Hemodialysis
Status: Enrolling
Updated: 1/10/2018
West Coast Clinical Trials, LLC
mi
from
Cypress, CA
Click here to add this to my saved trials
Study to Evaluate Daptomycin Given During Dialysis and After Dialysis
A Prospective, Randomized, Crossover-design Study to Evaluate the Pharmacokinetics and Safety of Daptomycin Administered at 9 mg/kg During and 6 mg/kg After Hemodialysis
Status: Enrolling
Updated:  1/10/2018
DaVita Clinical Research
mi
from
Minneapolis, MN
Study to Evaluate Daptomycin Given During Dialysis and After Dialysis
A Prospective, Randomized, Crossover-design Study to Evaluate the Pharmacokinetics and Safety of Daptomycin Administered at 9 mg/kg During and 6 mg/kg After Hemodialysis
Status: Enrolling
Updated: 1/10/2018
DaVita Clinical Research
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
Gift of Life Donor Program- Philadelphia
mi
from
Philadelphia, PA
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
Gift of Life Donor Program- Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
Gift of Life Michigan
mi
from
Ann Arbor, MI
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
Gift of Life Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
Harper University Hospital
mi
from
Detroit, MI
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
Harper University Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
New England Organ Bank
mi
from
Waltham, MA
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
New England Organ Bank
mi
from
Waltham, MA
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
New Jersey Sharing Network
mi
from
New Providence, NJ
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
New Jersey Sharing Network
mi
from
New Providence, NJ
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
New York Organ Donor Network
mi
from
New York, NY
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
New York Organ Donor Network
mi
from
New York, NY
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
St. Barnabas Medical Center
mi
from
Livingston, NJ
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
St. Barnabas Medical Center
mi
from
Livingston, NJ
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
Mount Sinai School of Medicine
mi
from
New York, NY
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
Yale-New Haven Hospital
mi
from
New Haven, CT
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
University of Maryland Medical Center
mi
from
Baltimore, MD
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
Newark Beth Israel Medical Center
mi
from
Newark, NJ
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
Newark Beth Israel Medical Center
mi
from
Newark, NJ
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
NewYork-Presbyterian/ Columbia University Irving Medical Center
mi
from
New York, NY
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
NewYork-Presbyterian/ Columbia University Irving Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
New York Hospital - Cornell
mi
from
New York, NY
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
New York Hospital - Cornell
mi
from
New York, NY
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
Montefiore Medical Center
mi
from
New York, NY
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
Montefiore Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
Hahnemann University Hospital
mi
from
Philadelphia, PA
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
Hahnemann University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated:  1/12/2018
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Deceased Donor Biomarkers and Recipient Outcomes
Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes
Status: Enrolling
Updated: 1/12/2018
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
A Single Dose, Randomized, Open-Label, Parallel Group Study Comparing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ticagrelor in Hemodialysis Patients to Subjects With Normal Renal Function
Status: Enrolling
Updated:  1/12/2018
Clinical Research Facility
mi
from
Lakewood, CO
Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
A Single Dose, Randomized, Open-Label, Parallel Group Study Comparing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ticagrelor in Hemodialysis Patients to Subjects With Normal Renal Function
Status: Enrolling
Updated: 1/12/2018
Clinical Research Facility
mi
from
Lakewood, CO
Click here to add this to my saved trials
Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
A Single Dose, Randomized, Open-Label, Parallel Group Study Comparing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ticagrelor in Hemodialysis Patients to Subjects With Normal Renal Function
Status: Enrolling
Updated:  1/12/2018
Clinical Research Facility
mi
from
Minneapolis, MN
Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
A Single Dose, Randomized, Open-Label, Parallel Group Study Comparing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ticagrelor in Hemodialysis Patients to Subjects With Normal Renal Function
Status: Enrolling
Updated: 1/12/2018
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Genetic Testing to Understand and Address Renal Disease Disparities
Genomic Medicine Pilot for Hypertension and Kidney Disease in Primary Care
Status: Enrolling
Updated:  1/16/2018
Institute for Family Health
mi
from
New York, NY
Genetic Testing to Understand and Address Renal Disease Disparities
Genomic Medicine Pilot for Hypertension and Kidney Disease in Primary Care
Status: Enrolling
Updated: 1/16/2018
Institute for Family Health
mi
from
New York, NY
Click here to add this to my saved trials
Genetic Testing to Understand and Address Renal Disease Disparities
Genomic Medicine Pilot for Hypertension and Kidney Disease in Primary Care
Status: Enrolling
Updated:  1/16/2018
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Genetic Testing to Understand and Address Renal Disease Disparities
Genomic Medicine Pilot for Hypertension and Kidney Disease in Primary Care
Status: Enrolling
Updated: 1/16/2018
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
Status: Enrolling
Updated:  1/17/2018
Ben Taub Hospital
mi
from
Houston, TX
Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
Status: Enrolling
Updated: 1/17/2018
Ben Taub Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Molecular MRI of the Fibrotic Heart
Molecular MRI of the Fibrotic Heart
Status: Enrolling
Updated:  1/18/2018
University of Kentucky Medical Center
mi
from
Lexington, KY
Molecular MRI of the Fibrotic Heart
Molecular MRI of the Fibrotic Heart
Status: Enrolling
Updated: 1/18/2018
University of Kentucky Medical Center
mi
from
Lexington, KY
Click here to add this to my saved trials